BR0315516A - Derivados de acila de 5-(2-(4-(1,2-benzoisotiazol-3-il)-1-piperazinil)etil)-6-clo ro-1,3-dihidro-2h-indol-2-ona tendo atividade neuroléptica - Google Patents

Derivados de acila de 5-(2-(4-(1,2-benzoisotiazol-3-il)-1-piperazinil)etil)-6-clo ro-1,3-dihidro-2h-indol-2-ona tendo atividade neuroléptica

Info

Publication number
BR0315516A
BR0315516A BR0315516-1A BR0315516A BR0315516A BR 0315516 A BR0315516 A BR 0315516A BR 0315516 A BR0315516 A BR 0315516A BR 0315516 A BR0315516 A BR 0315516A
Authority
BR
Brazil
Prior art keywords
indol
piperazinyl
dihydro
ethyl
benzoisothiazol
Prior art date
Application number
BR0315516-1A
Other languages
English (en)
Inventor
Timothy Norris
Roberto Colon-Cruz
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0315516A publication Critical patent/BR0315516A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

"DERIVADOS DE ACILA DE 5-(2-(4-(1,2-BENZOISO-TIAZOL-3-IL)-1-PIPERAZINIL)ETIL)-6-CLO RO-1,3-DIHIDRO-2H-INDOL-2-ONA TENDO ATIVIDADE NEUROLéPTICA". A presente invenção refere-se a um processo para preparar derivados de acila como pró-drogas de 5-(2-(4-(1,2-benzoisotiazol-3-il)-1-piperazinil)etil)-6-cloro-1,3-dihidro-2 H-indol-2-ona e sais de adição de ácidos farmaceuticamente aceitáveis e métodos de utilização como um antipsicótico.
BR0315516-1A 2002-10-24 2003-10-13 Derivados de acila de 5-(2-(4-(1,2-benzoisotiazol-3-il)-1-piperazinil)etil)-6-clo ro-1,3-dihidro-2h-indol-2-ona tendo atividade neuroléptica BR0315516A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42084302P 2002-10-24 2002-10-24
PCT/IB2003/004519 WO2004037819A1 (en) 2002-10-24 2003-10-13 Acyl derivatives of 5-(2-(4-(1,2 benzisothiazole-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one having neuroleptic activity

Publications (1)

Publication Number Publication Date
BR0315516A true BR0315516A (pt) 2005-08-23

Family

ID=32176638

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0315516-1A BR0315516A (pt) 2002-10-24 2003-10-13 Derivados de acila de 5-(2-(4-(1,2-benzoisotiazol-3-il)-1-piperazinil)etil)-6-clo ro-1,3-dihidro-2h-indol-2-ona tendo atividade neuroléptica

Country Status (24)

Country Link
US (1) US7019009B2 (pt)
EP (1) EP1556378B1 (pt)
JP (1) JP2006505578A (pt)
KR (1) KR100755625B1 (pt)
CN (1) CN100340557C (pt)
AR (1) AR041695A1 (pt)
AT (1) ATE383357T1 (pt)
AU (1) AU2003269331B2 (pt)
BR (1) BR0315516A (pt)
CA (1) CA2500485C (pt)
CO (1) CO5550441A2 (pt)
CY (1) CY1107300T1 (pt)
DE (1) DE60318602T2 (pt)
DK (1) DK1556378T3 (pt)
ES (1) ES2297200T3 (pt)
MX (1) MXPA05002734A (pt)
NO (1) NO20052475L (pt)
NZ (1) NZ566615A (pt)
PL (1) PL376721A1 (pt)
PT (1) PT1556378E (pt)
RU (1) RU2005112254A (pt)
TW (1) TW200418850A (pt)
WO (1) WO2004037819A1 (pt)
ZA (1) ZA200502109B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007517014A (ja) * 2003-12-31 2007-06-28 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー Ｎ−置換ピペリジン及びピペラジン誘導体
CA2937222C (en) * 2009-06-25 2019-06-04 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds
ES3031438T3 (en) 2009-06-25 2025-07-08 Alkermes Pharma Ireland Ltd Heterocyclic compounds for the treatment of neurological and psychological disorders
WO2011163594A2 (en) * 2010-06-24 2011-12-29 Alkermes, Inc. Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
CA3092335A1 (en) 2018-03-05 2019-09-12 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
ATE254600T1 (de) * 1996-02-13 2003-12-15 Pfizer Prodrogen von 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl ethyl)-6-chloro-1,3-dihydro-2h-indol- 2-on
JP4445133B2 (ja) * 1998-08-20 2010-04-07 大日本住友製薬株式会社 オキシインドール誘導体

Also Published As

Publication number Publication date
DK1556378T3 (da) 2008-03-17
ZA200502109B (en) 2006-05-31
NZ566615A (en) 2009-08-28
KR100755625B1 (ko) 2007-09-04
CA2500485A1 (en) 2004-05-06
TW200418850A (en) 2004-10-01
CO5550441A2 (es) 2005-08-31
NO20052475D0 (no) 2005-05-23
EP1556378B1 (en) 2008-01-09
AU2003269331A1 (en) 2004-05-13
US7019009B2 (en) 2006-03-28
US20040138232A1 (en) 2004-07-15
MXPA05002734A (es) 2005-05-23
AU2003269331B2 (en) 2010-02-18
NO20052475L (no) 2005-07-25
WO2004037819A1 (en) 2004-05-06
ATE383357T1 (de) 2008-01-15
PT1556378E (pt) 2008-02-21
AR041695A1 (es) 2005-05-26
CA2500485C (en) 2010-03-23
JP2006505578A (ja) 2006-02-16
PL376721A1 (pl) 2006-01-09
RU2005112254A (ru) 2006-01-20
ES2297200T3 (es) 2008-05-01
DE60318602D1 (de) 2008-02-21
CN100340557C (zh) 2007-10-03
CY1107300T1 (el) 2012-11-21
CN1705663A (zh) 2005-12-07
EP1556378A1 (en) 2005-07-27
KR20050065618A (ko) 2005-06-29
HK1081185A1 (en) 2006-05-12
DE60318602T2 (de) 2009-01-15

Similar Documents

Publication Publication Date Title
SG170785A1 (en) Benzothiazoles having histamine h3 receptor activity
EA200401136A1 (ru) Предназначенная для перорального применения лекарственная форма для этилового эфира 3-[(2-{[4-(гексилоксикарбониламиноиминометил)фениламино]метил}-1-метил-1h-бензимидазол-5-карбонил)пиридин-2-иламино]пропионовой кислоты и его солей
BR0209153A (pt) Indol, azaindol e derivados de amidopiperazina heterocìclicos relacionados
HUP9902808A2 (hu) 5-(2-(4-(1,2-Benzizotiazol-3-il)-1-piperazinil)-etil)-6-klór-1,3-dihidro-2-(1H)-indol-2-on (ziprazidon) mezilát-trihidrát sói, a vegyületek előállítása és dopamin D2 antagonistaként történő alkalmazása
DE60022504D1 (de) Phenoxypropylamin-derivate
BR0314393A (pt) Piperazinas heterocìclicas substituìdas para o tratamento de esquizofrenia
BR0311541A (pt) indol, azaindol e 4-aquenil piperidina amidas heterocìclicas relacionadas
ATE260275T1 (de) Substituierte thien-3-yl- sulfonylamino(thio)carbonyl-triazolin(thi)one
CA2252898A1 (en) Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2(1h)-indol-2-one(=ziprasidone), its preparation and its use as dopamine d2 antagonist
EA200971086A1 (ru) Фармацевтические композиции и способ лечения шизофрении
BRPI0409465A (pt) derivados de carboxamida como agentes antidiabéticos
BR0307894A (pt) Heterocìclos tricìclicos fundidos úteis para o tratamento de distúrbios hiperproliferativos
CY1107300T1 (el) Ακυλικα παραγωγα της 5-(2-(4-(1,2-βενζισοθειαζολ-3-υλο)-1-πιπεραζινυλ)αιθυλο)-6-χλωρο-1,3-διυδρο-2h-ινδολ-2-ονης με νευροληπτικη δραστικοτητα
BRPI0413223A (pt) artigo do vestuário descartável
BRPI0406704A (pt) Antagonistas de 5ht~7~ e agonistas inversos
DK0790236T3 (da) Prolægemidler af 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chlor-1,3-dihydro-2H-indol-2-on
EA200970044A1 (ru) Производные пирролидина, обладающие активностью в отношении транспортера glyt1
BR0307490A (pt) Derivado de piperidina e composição farmacêutica que compreende o mesmo como ingrediente ativo
BR0215560A (pt) Derivados de 2'-halo-3',5'-dialcoxifen-1'-il-imino-2-imidazolidina e o seu uso para o tratamento de incontinência urinária
IL188109A0 (en) Chloro-substituted guanidines
BR0315762A (pt) Utilização de derivados de ácidos piperazino-sulfónicos como antagonistas ccr1 para o tratamento de fibrose, doença de alzheimer e outras doenças
PE20011329A1 (es) S-metil-dihidro-ziprasidona para el tratamiento de trastornos psiquiatricos y oculares
DK1140810T3 (da) Benzensulfonamidderivater samt deres anvendelse
DK1421086T3 (da) 2-(Aminomethyl)-tetrahydro-9-oxa-1,3-diaza-cyclopenta[a]-naphthalenyl-derivater med antipsykotisk aktivitet
PT1330246E (pt) Utilizacao de derivados do acido hidroxieicosatetraenoico em cirurgia intraocular

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 9A E 10A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2256 DE 01/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 9A, 10A, 11A, 12A, 13A, 14A, 15A, 16A E 17A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.